{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:28:49Z","timestamp":1761560929059},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,11,15]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We conducted a multicenter phase II trial. Patients had pathologically staged T2 node-positive to T3-4, any node status adenocarcinoma of the distal esophagus, GE junction, or gastric cardia with negative margins (R0). Treatment consisted of four cycles of paclitaxel 175 mg\/m<jats:sup>2<\/jats:sup> intravenously (IV) over 3 hours followed by cisplatin 75 mg\/m<jats:sup>2<\/jats:sup> IV every 21 days. A positive outcome was considered to be an improvement in 2-year survival rate by \u2265 20% compared to historic controls. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Fifty-nine patients were recruited from 20 centers. Of 55 eligible patients, 49 (89%) had lymph node involvement. Forty-six patients (84%) completed all four cycles. Of the total 59 patients, 31 (56%) developed grade 3 or 4 toxicity with leukopenia\/neutropenia, nausea\/vomiting, and metabolic toxicities were most common. The median follow-up for surviving patients was 4 years. At 2 years, 33 patients were alive and 22 were dead, with a survival rate of 60% (95% CI, 46% to 73%; one-sided P = .0008 compared with the historic controls). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Our data suggest that adjuvant paclitaxel and cisplatin may improve survival in R0 resected patients with locally advanced adenocarcinoma of the distal esophagus, GE junction, and cardia. These results warrant further testing in randomized trials. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.06.533","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T23:27:57Z","timestamp":1100302077000},"page":"4495-4499","source":"Crossref","is-referenced-by-count":52,"title":["Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia: Phase II Trial (E8296) of the Eastern Cooperative Oncology Group"],"prefix":"10.1200","volume":"22","author":[{"given":"Mary","family":"Armanios","sequence":"first","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghui","family":"Xu","sequence":"additional","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene A.","family":"Forastiere","sequence":"additional","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Haller","sequence":"additional","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Kugler","sequence":"additional","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Al B.","family":"Benson","sequence":"additional","affiliation":[{"name":"From the Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Illinois Oncology Research Association, Peoria; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Schrump DS, Forastiere AA, Minsky BD: Cancer of the Esophagus, in DeVita V (ed): Cancer: Principles and Practice of Oncology.  Philadelphia, Lippincott Williams & Wilkins, pp 1051,2001-1091"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.305"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11228"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010187"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.095"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392704"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/11.3.168"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.2.75"},{"key":"R10","unstructured":"Kelsen D, Ajani J, Ilson D, et al: A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: Preliminary report. Semin Oncol 21:44,1994-48,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.14.1086"},{"key":"R12","unstructured":"Ilson DH, Forastiere A, Arquette M, et al: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6:316,2000-323,"},{"key":"R13","unstructured":"Kelsen D, Ginsberg R, Bains M, et al: A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: A preliminary report. Semin Oncol 24:S19-77,1997-S19-81,"},{"key":"R14","unstructured":"American Joint Committee on Cancer. Esophagus and Gastric (5th ed).  Philadelphia, J.B. Lippincott, 1997"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(97)00624-3"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.526"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2003.12.002"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200307000-00003"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608153350702"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370304"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04598-4"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.868"},{"key":"R24","unstructured":"Ajani JA, Faust J, Yao J, et al: Irinotecan\/cisplatin followed by 5-FU\/paclitaxel\/radiotherapy and surgery in esophageal cancer. Oncology (Huntingt) 17:20,2003-22,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.06.533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:58:10Z","timestamp":1653512290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.06.533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":24,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2004,11,15]]}},"alternative-id":["10.1200\/JCO.2004.06.533"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.06.533","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}